华蟾素胶囊联合XELOX化疗对局部晚期直肠癌患者疗效及预后生存的影响

Abstract
Figure/Table
References (19)
Related Citation (15)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the influences of Cinobufacin Capsules combined with Capecitabine plus Oxaliplatin(XELOX) regimen for neoadjuvant chemotherapy on therapeutic effects and prognosis in the treatment of locally advanced rectal cancer. Methods A total of 72 patients with rectal cancer admitted to Songzi Hospital of Traditional Chinese Medicine from March 2013 to March 2015 were selected as the research objects, they were divided into the study group and the control group according to the random number table method, with 36 cases in each group. The control group received neoadjuvant chemotherapy with XELOX regimen, and the study group received Cinobufacin capsules combined with XELOX regimen. Three weeks as one treatment course, both groups were treated for 2 courses.The clinical efficacy, survival rate, quality of life and adverse reactions were compared between the two groups. Results The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). The disease control rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). There was no significant difference in 1-year survival rate between the two groups (P>0.05); the 2-year and 3-year survival rates in the study group were higher than those in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the quality of life score between the two groups before treatment(P>0.05);the quality of life scores of the two groups at 1 and 3 months after treatment were higher than those before treatment of this group, the quality of life scores at 3 months after treatment were higher than those at 1 month after treatment in both groups, and the quality of life score of the study group was higher than that of the control group 1 and 3 months after treatment, and the differences were statistically significant(P<0.05). There was no significant difference in the adverse reactions between the two groups (P>0.05). Conclusion Cinobufacin Capsules combined with XELOX regimen for neoadjuvant chemotherapy in the treatment of locally advanced rectal cancer can significantly improve the total effective rate of clinical treatment and disease control rate, prolong the survival time of patients, improve their quality of life, at the same time, it does not increase adverse reactions.

Key words： Cinobufacin Capsules Capecitabine Oxaliplatin;Advanced rectal cancer;Therapeutic effect;Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Zhi-yan

Cite this article:

ZHANG Zhi-yan. The influences of Cinobufacin Capsules combined with XELOX regimen for neoadjuvant chemotherapy on therapeutic effects and prognosis in the treatment of locally advanced rectal cancer[J]. 中国当代医药, 2021, 28(21): 29-32.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I21/29

[1]	陈宏达，代敏.中国结直肠癌预防和控制的思考[J].中华流行病学杂志，2020，41（10）：1627-1632.
[2]	马骏，张玉英，陈树军，等.奥沙利铂不同给药方案联合卡培他滨对结直肠癌肝转移患者的疗效及生存率的影响[J].中国医药，2020，15（4）：593-596.
[3]	朱晓静.华蟾素胶囊联合FOLFIRI 化疗治疗晚期直肠癌患者的疗效及安全性分析[J].哈尔滨医药，2020，40（2）：148-149.
[4]	Lencioni R，Llovet JM.Modified RECIST（mRECIST）assessment for hepatocellular carcinoma[J].Semin Liver Dis，2010，30（1）：52-60.
[5]	Sherbourne CD，Ware JE.The MOS 36-item short-form health survey（SF-36）[J].Med Care，1992，30（6）：473-483.
[6]	张宇涛.结直肠癌的治疗进展[J].山西医药杂志，2020，49（5）：535-536.
[7]	Ducreux M，Bennouna J，Hebbar M，et al.Capecitabine plus oxaliplatin （XELOX）versus 5-fluorouracil/leucovorin plus oxaliplatin（FOLFOX-6）as first-line treatment for metastatic colorectal cancer[J].Int J Cancer，2015，128（3）：682-690.
[8]	李心翔，李清国.局部进展期直肠癌行新辅助放化疗后辅助化疗的争议与进展[J].中华胃肠外科杂志，2019，22（6）：594-596.
[9]	付洪涛，聂少麟，唐艳艳.新辅助化疗治疗Ⅲ期结直肠癌术后患者整体生存率的Meta 分析[J].肿瘤药学，2019，9（2）：317-324.
[10]	Soda H，Maeda H，Hasegawa J，et al.Multicenter Phase Ⅱstudy of FOLFOX or biweekly XELOX and Erbitux（cetuximab）as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer：The FLEET study[J].Bmc Cancer，2015，15（1）：695.
[11]	谢馨，李明，吴业.结直肠癌患者经XELOX 与卡培他滨单药治疗的临床疗效及生活质量影响观察[J].黑龙江医药，2020，33（2）：326-327.
[12]	Kataoka M，Kanda M，Ishigure K，et al.The COMET Openlabel Phase ⅡStudy of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer[J].Ann Surg Oncol，2016，24（2）：1-8.
[13]	苏建伟，周喜汉.XELOX 化疗方案与FOLFOX4 化疗方案治疗晚期结直肠癌的效果及安全性对比[J].当代医药论丛，2020，18（9）：135-137.
[14]	张德志，刘猛，朱少功，等.XELOX 方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J].中国临床药理学与治疗学，2020，25（8）：926-936.
[15]	彭莹莹，陈哲，王方园，等.华蟾素胶囊联合奥沙利铂化疗方案治疗结直肠癌的Meta 分析[J].中医学报，2020，35（3）：673-678.
[16]	韩娜娜.华蟾素胶囊联合FOLFOX6 方案治疗79 例晚期直肠癌的临床研究[J].北方药学，2019，16（2）：89-90.
[17]	沙晓锋，宋增芳，丁洁，等.华蟾素胶囊联合雷替曲塞与奥利沙铂对晚期结直肠癌免疫、肿瘤标记物、基质金属蛋白酶及血管新生的影响[J].海南医学院学报，2018，24（23）：2066-2069.
[18]	李玲.华蟾素胶囊联合含卡培他滨基础方案治疗晚期乳腺癌疗效及对相关血清指标的影响[J].当代医学，2020，26（1）：91-93.
[19]	陈海婷，卞伟钢，周小宁，等.华蟾素胶囊对中晚期癌症患者癌性疼痛的改善作用[J].中医药临床杂志，2019，31（5）：947-949.